Figure 3 shows the results (median) of parameters characterizing metabolic disorders, including SIRT-1, -3, and -6; IRS; MNST; PYY; GLP-1; and DDP-4, before, after 1 year, and after 5 years of cART use in the MLWH subgroups treated with two therapeutic regimens (INSTIs and PIs). This evidence concerns the gene SIRT1 and metabolic disease.